{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:22Z","timestamp":1786981762317,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04641-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:59:45Z","timestamp":1751403585000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy"],"prefix":"10.1007","volume":"58","author":[{"given":"Tae Ho","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Dong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Ryeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kwon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"3","key":"4641_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4641_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4641_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4143\/crt.2025.264","volume":"57","author":"EH Park","year":"2025","unstructured":"Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ et al (2025) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022. Cancer Res Treat 57(2):312\u2013330. https:\/\/doi.org\/10.4143\/crt.2025.264","journal-title":"Cancer Res Treat"},{"issue":"2","key":"4641_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4143\/crt.2025.263","volume":"57","author":"KW Jung","year":"2025","unstructured":"Jung KW, Kang MJ, Park EH, Yun EH, Kim HJ, Kim JE et al (2025) Prediction of cancer incidence and mortality in Korea, 2025. Cancer Res Treat 57(2):331\u2013338. https:\/\/doi.org\/10.4143\/crt.2025.263","journal-title":"Cancer Res Treat"},{"issue":"1","key":"4641_CR5","doi-asserted-by":"publisher","first-page":"e2456825","DOI":"10.1001\/jamanetworkopen.2024.56825","volume":"8","author":"EL Van Blarigan","year":"2025","unstructured":"Van Blarigan EL, McKinley MA, Washington SL 3rd, Cooperberg MR, Kenfield SA, Cheng I et al (2025) Trends in prostate cancer incidence and mortality rates. JAMA Netw Open 8(1):e2456825. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825","journal-title":"JAMA Netw Open"},{"issue":"6","key":"4641_CR6","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046\u20131055. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062","journal-title":"Eur Urol"},{"issue":"2","key":"4641_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244\u2013252. https:\/\/doi.org\/10.1097\/PAS.0000000000000530","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"4641_CR8","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jnci\/djab131","volume":"113","author":"F Islami","year":"2021","unstructured":"Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL et al (2021) Annual report to the nation on the status of cancer, Part 1: National cancer statistics. J Natl Cancer Inst 113(12):1648\u20131669. https:\/\/doi.org\/10.1093\/jnci\/djab131","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"4641_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/jnci\/djp278","volume":"101","author":"HG Welch","year":"2009","unstructured":"Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005. J Natl Cancer Inst 101(19):1325\u20131329. https:\/\/doi.org\/10.1093\/jnci\/djp278","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4641_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bju.16280","volume":"133","author":"R Talwar","year":"2024","unstructured":"Talwar R, Akinsola O, Penson DF (2024) What is cancer? A focus on Grade Group 1 prostate cancer. BJU Int 133(4):360\u2013364. https:\/\/doi.org\/10.1111\/bju.16280","journal-title":"BJU Int"},{"issue":"6","key":"4641_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1097-0215(20001220)90:6<305::aid-ijc1>3.0.co;2-u","volume":"90","author":"CR King","year":"2000","unstructured":"King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90(6):305\u2013311. https:\/\/doi.org\/10.1002\/1097-0215(20001220)90:6%3c305::aid-ijc1%3e3.0.co;2-u","journal-title":"Int J Cancer"},{"issue":"4","key":"4641_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/iju.12326","volume":"21","author":"TH Kim","year":"2014","unstructured":"Kim TH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS et al (2014) Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int J Urol 21(4):377\u2013381. https:\/\/doi.org\/10.1111\/iju.12326","journal-title":"Int J Urol"},{"issue":"1","key":"4641_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/JU.0000000000002956","volume":"209","author":"K Shee","year":"2023","unstructured":"Shee K, Washington SL 3rd, Cowan JE, de la Calle CM, Baskin AS, Chappidi MR et al (2023) Gleason Grade 1 prostate cancer volume at biopsy is associated with upgrading but not adverse pathology or recurrence after radical prostatectomy: results from a large institutional cohort. J Urol 209(1):198\u2013207. https:\/\/doi.org\/10.1097\/JU.0000000000002956","journal-title":"J Urol"},{"issue":"27","key":"4641_CR14","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.22.00123","volume":"40","author":"SE Eggener","year":"2022","unstructured":"Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR (2022) Low-grade prostate cancer: time to stop calling it cancer. J Clin Oncol 40(27):3110\u20133114. https:\/\/doi.org\/10.1200\/JCO.22.00123","journal-title":"J Clin Oncol"},{"issue":"6","key":"4641_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.euf.2023.04.002","volume":"9","author":"R Saoud","year":"2023","unstructured":"Saoud R, Woranisarakul V, Paner GP, Ramotar M, Berlin A, Cooperberg M et al (2023) Physician perception of Grade Group 1 prostate cancer. Eur Urol Focus 9(6):966\u2013973. https:\/\/doi.org\/10.1016\/j.euf.2023.04.002","journal-title":"Eur Urol Focus"},{"issue":"4","key":"4641_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.juro.2017.10.010","volume":"199","author":"F Audenet","year":"2018","unstructured":"Audenet F, Vertosick EA, Fine SW, Sjoberg DD, Vickers AJ, Reuter VE et al (2018) Biopsy core features are poor predictors of adverse pathology in men with Grade Group 1 prostate cancer. J Urol 199(4):961\u2013968. https:\/\/doi.org\/10.1016\/j.juro.2017.10.010","journal-title":"J Urol"},{"key":"4641_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.euros.2022.12.002","volume":"48","author":"A Ramaswamy","year":"2023","unstructured":"Ramaswamy A, Proudfoot JA, Ross AE, Davicioni E, Schaeffer EM, Hu JC (2023) Prostate cancer tumor volume and genomic risk. Eur Urol Open Sci 48:90\u201397. https:\/\/doi.org\/10.1016\/j.euros.2022.12.002","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"4641_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.eururo.2009.07.053","volume":"56","author":"G Ploussard","year":"2009","unstructured":"Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A et al (2009) The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 56(6):891\u2013898. https:\/\/doi.org\/10.1016\/j.eururo.2009.07.053","journal-title":"Eur Urol"},{"key":"4641_CR19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0361-OA","author":"EI Verhoef","year":"2020","unstructured":"Verhoef EI, Kweldam CF, Kummerlin IP, Nieboer D, Bangma CH, Incrocci L et al (2020) Comparison of tumor volume parameters on prostate cancer biopsies. Arch Pathol Lab Med. https:\/\/doi.org\/10.5858\/arpa.2019-0361-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"4641_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.juro.2007.10.060","volume":"179","author":"F Dong","year":"2008","unstructured":"Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA (2008) Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 179(3):896\u2013900. https:\/\/doi.org\/10.1016\/j.juro.2007.10.060. (discussion)","journal-title":"J Urol"},{"issue":"3","key":"4641_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2018.05.035","volume":"75","author":"AR Padhani","year":"2019","unstructured":"Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J (2019) Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. Eur Urol 75(3):385\u2013396. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.035","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04641-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T20:01:36Z","timestamp":1768161696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04641-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4641"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04641-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}